Tenax Therapeutics Inc
NASDAQ:TENX

Watchlist Manager
Tenax Therapeutics Inc Logo
Tenax Therapeutics Inc
NASDAQ:TENX
Watchlist
Price: 12.85 USD -3.17% Market Closed
Market Cap: 80.2m USD

During the last 3 months Tenax Therapeutics Inc insiders bought 160.3k USD , and have not sold any shares. The stock price has increased by 64% over this period (open performance analysis).

The last transaction was made on Dec 9, 2025 by Rich Stuart , who bought 25.5k USD worth of TENX shares.

Last Transactions:
Rich Stuart
$+25.5k
Rich Stuart
Chief Executive Officer
$+25.3k
Rich Stuart
$+23k
Rich Stuart
Chief Executive Officer
$+13.6k
Rich Stuart
Chief Executive Officer
$+9k
Giordano Christopher Thomas
$+4.1k
Giordano Christopher Thomas
President and Chief Executive Officer
$+3.4k
Giordano Christopher Thomas
President and Chief Executive Officer
$+12.5k
Almenoff June Sherie
President and Chief Operating Officer
$+14.3k
Almenoff June Sherie
$+14.3k
Almenoff June Sherie
President and Chief Operating Officer
$+665
Mcgauley Thomas
Chief Executive Officer
$+14.7k
Armistice Capital, Llc
$+7.3
Armistice Capital, Llc
$+21.2
Armistice Capital, Llc
$+32
Armistice Capital, Llc
$+19.1
Armistice Capital, Llc
$+27.7
Armistice Capital, Llc
$+18.9
Armistice Capital, Llc
$+12
Armistice Capital, Llc
$+12
Armistice Capital, Llc
$+16.8
Armistice Capital, Llc
$+5.9
Armistice Capital, Llc
$+105.1
Armistice Capital, Llc
$+119.3
Armistice Capital, Llc
$+63.8
Blanck Ronald R
$+2.9
Blanck Ronald R
$+0
Blanck Ronald R
$-0
Proehl Gerald T
$+0
Proehl Gerald T
$+0
Mitchum James P.
$+0
Mitchum James P.
$+0
View All Transactions

During the last 3 months Tenax Therapeutics Inc insiders bought 160.3k USD , and have not sold any shares. The stock price has increased by 64% over this period (open performance analysis).

The last transaction was made on Dec 9, 2025 by Rich Stuart , who bought 25.5k USD worth of TENX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
4
160.3k USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Tenax Therapeutics Inc
Insider Trading Chart

Tenax Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Tenax Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Tenax Therapeutics Inc
Glance View

Market Cap
75.9m USD
Industry
Biotechnology

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company is headquartered in Morrisville, North Carolina and currently employs 8 full-time employees. The firm's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The firm's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for the treatment of pulmonary arterial hypertension (PAH), which is a fatal orphan disease. The firm has completed Phase II clinical trial of levosimendan in North America for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

TENX Intrinsic Value
Not Available

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top